SIRT1 in secretory organ cancer

Research output: Contribution to journalReview articlepeer-review


© 2007 - 2018 Frontiers Media S.A. All Rights Reserved. Mammalian silent information regulator 1 (SIRT1) is reported to play a role in cancers of the secretory organs, including thyroid, pancreatic endocrine, and ovarian tumors (1, 2, 3, 4). A recent meta-analysis conducted on 37 selected studies of human cancers analyzed the correlations of overall survival (OS), disease-free survival (DFS) and relapse-free survival (RFS) with SIRT1 expression (5). This study reported that SIRT1 overexpression was associated with a worse OS in liver and lung cancers, while it was not correlated with OS in breast cancer, colorectal cancer, or gastric carcinoma. Collectively, the meta-analysis revealed that an unfavorable OS was associated with SIRT1 expression for solid malignancies. Given the growing importance of this class of lysine/histone deacetylases in human endocrine malignancies, a rational and focused literature assessment is desirable in light of future clinical translations.
Original languageEnglish
JournalFrontiers in Endocrinology
Issue numberSEP
Publication statusPublished - Sep 24 2018


  • Acetylation
  • Cancer
  • Epigenetic modulation
  • Secretory organs
  • SIRT1


Dive into the research topics of 'SIRT1 in secretory organ cancer'. Together they form a unique fingerprint.

Cite this